Location History:
- Longmont, CO (US) (2006 - 2010)
- Hopkinton, MA (US) (2010)
- Cambridge, MA (US) (2019 - 2021)
Company Filing History:
5 out of 6 
3 out of 1,179 
2 out of 164 
Years Active: 2006-2021
Title: The Innovations of Scott Douglas Cowen
Introduction: Scott Douglas Cowen, an accomplished inventor based in Longmont, Colorado, has made significant contributions to the field of pharmaceuticals. With a total of five patents to his name, he has focused his research on developing innovative compounds that target critical biological processes. His work has the potential to impact treatment options for various health conditions.
Latest Patents: Among his most recent innovations are patents concerning Dipeptidyl Peptidase (DPP-IV) inhibitors. These patents detail compounds, pharmaceuticals, kits, and methods designed for use with DPP-IV inhibitors, featuring specific formulae where substituents are properly described. These advancements showcase Cowen's dedication to exploring new therapeutic avenues in the pharmaceutical landscape.
Career Highlights: Scott has worked with notable companies such as Takeda Pharmaceutical Company Limited and Icos Corporation. His experience in these esteemed organizations has provided him with a strong foundation to further his research and development in pharmaceuticals.
Collaborations: Throughout his career, Cowen has collaborated with skilled professionals, including Laurence Edward Burgess and Stephen L. Gwaltney. These partnerships have likely enriched his work, allowing for a diverse range of ideas and perspectives to influence his innovative projects.
Conclusion: Scott Douglas Cowen stands out as a prominent figure in his field, with a proven track record of innovation and collaboration. His patents related to Dipeptidyl Peptidase inhibitors reflect his commitment to enhancing pharmaceutical treatments. As he continues to develop his work, the impact of his inventions may lead to significant advancements in medical science.